Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

TARO PHARMACEUTICAL INDUSTRIES LTD (TAROF)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsMar-31-23Mar-31-22Mar-31-21Mar-31-20Mar-31-19Mar-31-18Mar-31-17Mar-31-16
   20-F20-F20-F20-F20-F20-F20-F20-F
    Total interest income  6.61.32.411.714.113.414.513.1
Net interest income  6.61.32.411.714.113.414.513.1
Pre-tax income before non-recurring items  40.782.1-388.2301.1355.0296.1561.1639.8
Non-recurring items  2.54.22.93.0-1.93.8 3.0
Asset impairment        0.3 
Pre-tax income  38.277.9-391.1298.0356.9292.4560.8636.8
Income taxes  12.819.69.753.574.782.0103.895.3
            Tax rate  33.4%25.2% 17.9%20.9%28.0%18.5%15.0%
Minority interest      0.3-1.10.30.3
Earnings from continuing ops  25.458.3-386.7244.2281.8421.9913.71,082.7
Earnings from discontinued ops       -0.3-0.4-0.2
Net income  25.458.3-386.7244.2281.8421.6913.41,082.4
            Net margin  4.4%10.4%-70.4%37.9%42.1%63.7%103.9%113.9%
   
Basic EPS  $0.68$1.55($10.12)$6.35$7.23$10.51$22.12$25.28
Diluted EPS  $0.68$1.55($10.12)$6.35$7.23$10.51$22.12$25.28
   
Shares outstanding (basic)  37.637.638.238.539.040.241.342.8
Shares outstanding (diluted)  37.637.638.238.539.040.241.342.8
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy